Ambys Medicines
131 Oyster Point Blvd. Suite 200
South San Francisco, CA 94080
United States
21 articles about Ambys Medicines
-
Ambys Medicines Announces Formation of Clinical and Scientific Advisory Boards with Leading Liver Disease and Cell and Gene Therapy Experts
6/27/2022
Ambys Medicines , a company pioneering cell-replacement therapies for patients with liver disease, today announced the formation of its clinical and scientific advisory boards comprising leading clinical experts in liver disease and hepatocyte transplantation, and world-class scientists pioneering cell and gene technologies.
-
Ambys Medicines to Present Data from Universal Human Hepatocyte Program at the 2022 ISSCR Annual Meeting
6/9/2022
Ambys Medicines , a company pioneering cell-replacement therapies for patients with liver disease, today announced that data from its universal hepatocyte program will be presented at the 2022 International Society for Stem Cell Research (ISSCR) Annual Meeting, which will be held June 15-18, 2022, in San Francisco and virtually.
-
Ambys Medicines Presents New Data Further Validating its Novel Liver Cell Replacement Therapy Platform at the ASGCT Annual Meeting
5/18/2022
Ambys Medicines, a company pioneering cell-replacement therapies for patients with liver disease, announced new data on its universal hepatocyte program in an oral presentation at the American Society of Gene and Cell Therapy 25th Annual Meeting at 3:45 p.m. ET.
-
Ambys Medicines to Present New Data on Liver Cell Replacement Therapy Platform at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
5/9/2022
Ambys Medicines today announced that new data from its novel hepatocyte cell therapy platform and universal hepatocyte program will be highlighted in three presentations at the American Society of Gene and Cell Therapy (ASGCT) 25th Annual Meeting, which will be held on May 16-19, 2022, in Washington, D.C.
-
Biopharma and life sciences organizations strengthen their leadership teams and boards with these Movers & Shakers.
-
Ambys Medicines Expands Leadership Team with Key Appointments in Human Resources and Finance Functions
4/20/2022
Ambys Medicines, a company pioneering cell-replacement therapies for patients with liver failure, today announced the expansion of its leadership team with the appointments of Samira Shaikhly as Chief Human Resources Officer and John McKeon as Vice President of Finance.
-
BioSpace Movers & Shakers, Jan. 21
1/21/2022
Biopharma and life sciences companies made numerous appointments this week to boards and executive teams. These Movers & Shakers will position the companies for future growth. -
Ambys Medicines Appoints Dr. Corinne Foo-Atkins as Chief Strategy Officer
1/20/2022
Ambys Medicines, a company pioneering cell-based therapies for severe liver diseases, today announced the appointment of Corinne Foo-Atkins, MBBS, MBA, MSc, as the company’s first Chief Strategy Officer.
-
Money on the Move: December 15 – 21
12/22/2021
These biotech companies made the nice list, earning them far more than a lump of coal. -
Ambys Completes $47 Million Series A Extension to Advance Liver Cell Therapy Platform
12/21/2021
Ambys Medicines, a company pioneering cell-based therapies for severe liver diseases, today announced it has completed a $47 million extension of its Series A financing.
-
Ambys Medicines Announces Appointment of Founder Markus Grompe, M.D., as Chief Scientific Officer
12/6/2021
Ambys Medicines, a company aiming to be the leader in cell therapy for severe liver disease by unlocking the full potential of hepatocyte transplantation, today announced the appointment of Markus Grompe, M.D., as the company’s Chief Scientific Officer.
-
Ambys Medicines Announces John Choi is Joining as VP of Regulatory Affairs as it Initiates IND Activities for its Lead Allogeneic Liver Cell Transplantation Program
10/13/2021
Ambys Medicines, a cell and gene therapy company focused on transforming the treatment of severe liver disease by unlocking the full potential of hepatocyte transplantation, announced that John Choi, MS, RAC, has joined as Vice President, Regulatory Affairs.
-
BioSpace Movers & Shakers, June 4
6/4/2021
Biopharma and life sciences organizations strengthen their leadership teams and board with these Movers & Shakers. -
Ambys Medicines Appoints Ronald Park, M.D., Chief Executive Officer
6/1/2021
Ambys Medicines, a cell and gene therapy company focused on advancing novel treatments to restore and regenerate liver function, today announced the appointment of Ronald Park, M.D., as the company's new Chief Executive Officer. Dr. Park also joins the Ambys board of directors.
-
Ambys Medicines Appoints Alan Smith, Ph.D., Chief Technology Officer
4/21/2021
Ambys Medicines, a cell and gene therapy company focused on advancing novel treatments to restore and regenerate liver function, announced today the appointment of Alan Smith, Ph.D., as the company's new Chief Technology Officer.
-
Ambys Medicines Expands Board of Directors with Appointment of Jennifer Cook
10/14/2020
-- Former GRAIL CEO and Roche/Genentech senior executive brings extensive product development and commercialization expertise to liver therapeutics pioneer -- SOUTH SAN FRANCISCO, Calif.--( BUSINESS WIRE )-- Ambys Medicines, a cell and gene therapy company focused on advancing novel treatments to restore and regenerate liver function, today announced the appointment of Jennifer Cook to its Board of Directors. A highly respected biotechnology and
-
Check out this article for the impacts that Biotech Bay companies are experiencing due to COVID-19.
-
Biotech and pharma companies tap new members of executive leadership teams and boards.
-
Ambys Medicines Appoints Deidre Roniger as Senior Vice President of Corporate Development and Amanda Valentino as Chief People Officer
6/25/2019
Genentech alumna to lead Ambys’ business strategy and growth initiatives to support company’s focus on pioneering regenerative medicine for advanced liver diseases
-
BioSpace is proud to present its NextGen Bio “Class of 2019,” a list of 20 up-and-coming life science companies in North America that launched* no earlier than 2017.